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Advanced prostate cancer comprises several clinical-pathologic states characterized as incurable due to 
the presence of locally advanced or metastatic disease. 
The disease is considered locally advanced when it has 
extended beyond the confines of the prostate gland, 
which can also involve adjacent structures or pelvic 
lymph nodes. Metastatic prostate cancer occurs when 
the disease has spread to sites remote from the pri-
mary tumor (eg, bones or distant lymph nodes); it is 
a fatal condition, with a 5-year relative survival rate of 
about 30% (1). Because treatment-naive prostate can-
cers are sensitive to hormonal treatment (also known 
as hormone-sensitive prostate cancer), combination 
treatments with androgen deprivation therapy are the 
mainstay treatments for advanced and metastatic pros-
tate cancer at initial diagnosis. Patients who have disease 
progression while undergoing androgen deprivation 
therapy enter a clinical state called castration-resistant 
prostate carcinoma (CRPC). The prevalence of meta-
static disease is greatest in men with high risk (accord-
ing to established clinical and pathologic criteria) and 
locally advanced disease and in those with castration-
resistant disease. Patients who have CRPC with rising 
prostate-specific antigen (PSA) levels and without me-
tastases that can be detected with imaging (CT or bone 
scans) are classified as having M0 CRPC disease and are 
considered to have advanced prostate cancer (Fig E1 
[online]).
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The management of advanced prostate cancer has changed substantially with the availability of multiple effective novel treatments, 
which has led to improved disease survival. In the era of personalized cancer treatments, more precise imaging may help physicians 
deliver better care. More accurate local staging and earlier detection of metastatic disease, accurate identification of oligometastatic 
disease, and optimal assessment of treatment response are areas where modern imaging is rapidly evolving and expanding. Next-
generation imaging modalities, including whole-body MRI and molecular imaging with combined PET and CT and combined 
PET and MRI using novel radiopharmaceuticals, create new opportunities for imaging to support and refine management pathways 
in patients with advanced prostate cancer. This article demonstrates the potential and challenges of applying next-generation imag-
ing to deliver the clinical promise of treatment breakthroughs.
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imaging theranostics in guiding patient care. Some of the 
potential and challenges of next-generation imaging are also 
discussed.
Advanced Prostate Cancer Imaging at 
Staging and during Follow-up
Imaging investigations of prostate cancer are more informa-
tive when physicians have knowledge of a patient’s clinical 
findings and symptoms, risk status, likely testosterone level, 
and perceived risk of metastatic disease. When we apply the 
National Comprehensive Cancer Network, or NCCN, 2018 
(8) and European Association of Urology, European Society 
for Radiotherapy and Oncology, and International Society of 
Geriatric Oncology (hereafter, EAU-ESTRO-SIOG) (9) man-
agement guidelines, patients who present with intermediate- 
or high-risk locally advanced disease are usually referred for 
imaging to detect metastatic disease (Fig 1). Imaging is also 
performed when disease relapse is suspected, usually based on 
rising serum PSA levels (biochemical recurrence), in patients 
who have undergone curative treatment (8,9). Once disease is 
confirmed, subsequent imaging is performed to assess therapy 
response and complications. The frequency of imaging assess-
ment is guided by the prostate cancer state (hormone sensi-
tive or castration resistant), anatomic location, and extent of 
metastatic disease (Fig 2).
The volume of disease at presentation and during initial 
biochemical recurrence and biochemical failure while under-
going systemic therapy are highly prognostic, affecting ther-
apy options. In patients with only a few (5) demonstrable 
sites of metastatic disease described as oligometastatic disease 
(10), more aggressive metastasis-directed treatments can be 
considered, such as targeted radiation therapy, surgery, or lo-
cal ablative procedures. However, the impact of such treat-
ments is still being investigated (11).
Systemic treatment responses are usually monitored with 
a combination of imaging, clinical assessments, measurement 
of the serum PSA level, and evaluation of other biochemi-
cal indexes. Imaging plays a relatively minor role if patients 
are responding clinically and with blood biomarkers in those 
with hormone-sensitive states. If first-line androgen depriva-
tion therapy becomes ineffective, patients move into a CRPC 
state (with suppressed serum testosterone levels). This situa-
tion is associated with a high incidence of metastatic disease; 
thus, other life-prolonging or palliative therapies are consid-
ered. Patients with CRPC who do not have metastatic disease 
that is visible at imaging can also be considered for newer 
therapies (12).
Imaging Assessment of Advanced Prostate 
Cancer
Prostate cancer has a propensity to spread to the bones, lymph 
nodes, liver, lungs, and—rarely—brain (13,14). Up to 62% 
of patients with newly diagnosed metastatic prostate cancer 
(13) and more than 40% of patients with CRPC (14) have 
metastatic disease confined to the skeletal system. When pa-
tients undergo multiple treatments with different drugs, vis-
Abbreviations
CRPC = castration-resistant prostate cancer, DW = diffusion weighted, 
FDG = fluorodeoxyglucose, FDHT = 16-b-fluoro-5-a-dihydrotestos-
terone, MET-RADS-P = METastasis Reporting and Data System for 
Prostate Cancer, PSA = prostate-specific antigen, PSMA = prostate-
specific membrane antigen, RECIST = Response Evaluation Criteria In 
Solid Tumors, SUV = standardized uptake value, USPIO = ultrasmall 
superparamagnetic iron oxide
Summary
Whole-body diffusion-weighted MRI and molecular imaging will 
play increasing roles in defining the presence and extent of metastatic 
disease, enabling assessment of treatment response and disease pro-
gression, and will improve our understanding of disease biology.
Essentials
 n Conventional imaging with CT and bone scanning has limited 
sensitivity to depict nodal and bone disease in prostate cancer.
 n Next-generation imaging, including whole-body diffusion-weighted 
MRI with novel radiopharmaceuticals for combined PET and CT 
and combined PET and MRI, is more accurate in defining the 
presence and extent of disease.
 n Next-generation imaging enables earlier initiation of treatment in 
patients with occult metastatic disease at CT and bone scanning; 
optimal change in treatment via earlier detection of disease pro-
gression; detection of oligometastatic state (limited metastatic dis-
ease), which may be treated more aggressively; guidance of tissue 
biopsies for molecular tumor characterization; and development of 
novel predictive and prognostic biomarkers to guide therapies.
Research has shown considerable inter- and intrapatient 
heterogeneity of disease biology at the genetic and molecular 
levels (2), with advancing disease before and during therapy. 
Tumor heterogeneity is thought to underlie response hetero-
geneity to treatments, contributing to the development of re-
sistance. The increasing number of life-prolonging therapies 
for advanced prostate cancer demands improved molecular 
stratification and predictive biomarkers to optimize patient 
treatment. Emerging predictive molecular biomarkers to new 
therapies include BRCA gene mutation, androgen receptor 
splice variants (3), phosphatase and tensin homolog loss (4), 
homologous recombination deoxyribonucleic acid repair de-
fects (5), and mismatch repair defects (6). Modern imaging 
contributes to advanced prostate cancer management by de-
fining the presence and extent of tumor, enabling imaging-tar-
geted metastatic disease sampling, depicting disease response, 
and allowing earlier detection of treatment failure. Modern 
imaging, together with imaging-targeted tissue sampling 
and molecular biomarkers, can improve the understanding 
of prostate cancer biology by elucidating the development of 
therapy resistance and evolution of metastases (6,7).
In this review, we discuss the roles of established (CT and 
bone scanning) and next-generation imaging technologies, 
including whole-body MRI and PET, combined PET and 
CT, and combined PET and MRI, in defining the presence 
and extent of disease to support modern advanced prostate 
cancer management. We discuss the emerging role of imag-
ing in the evaluation of oligometastatic disease, recognize 
the growing importance of imaging in the evaluation of dis-
ease response to treatment, and appreciate the potential for 
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tate cancer surgery has been largely 
guided by clinical nomography. Im-
aging has been used to guide nodal 
dissections to suspicious sites outside 
the “normal surgical field” (9,18,19). 
Molecular and functional imaging 
techniques are being investigated to 
improve the accuracy of nodal me-
tastasis detection and to guide nodal 
sampling at surgery (20).
MRI.—Diffusion-weighted (DW) 
MRI is sensitive to differences in the 
mobility of water between tissues 
and enables calculation of the ap-
parent diffusion coefficient (ADC). 
Malignant nodes return lower ADC 
values than do benign lymph nodes, 
but there is overlap of ADC values 
between malignant and nonmalig-
nant nodes (21). On per-patient 
level and per–pelvic side-wall nodes 
level subanalyses, negative likelihood 
ratios are not low enough to avoid 
or lateralize lymphadenectomy. This 
is relevant as pelvic side-wall nodes 
are the most frequent site of meta-
static disease from prostate cancer and define the extension 
of surgery. However, positive likelihood ratios are sufficiently 
high to increase the extent of planned lymphadenectomy 
or prophylactic pelvic nodal irradiation if suspicious nodes 
are seen outside planned surgical or radiation therapy fields 
(21). There has been hope that use of a lymphotrophic ul-
trasmall superparamagnetic iron oxide (USPIO) MRI con-
trast medium (Fig 3) (22,23) can improve malignant lymph 
node detection, especially when combined with DW imaging 
(22,23). Meta-analysis showed that DW MRI with a USPIO 
had higher diagnostic sensitivity compared with conventional 
MRI without the USPIO (24). In a study evaluating 2993 
normal-size lymph nodes in patients with prostate or blad-
der cancer, combining DW MRI with a USPIO improved 
diagnostic sensitivity and specificity (range, 65%–75% and 
93%–96%, respectively) compared with sensitivity and speci-
ficity of MRI with a USPIO alone (range, 55%–65% and 
71%–91%, respectively) (22). However, USPIO MRI did 
not demonstrate clinical utility in phase III studies, and it 
remains commercially unavailable for nodal imaging.
PET/CT and PET/MRI.—Fluorine 18 (18F) fluorodeoxyglu-
cose (FDG) has poor performance in patients with prostate 
cancer (25) because prostate cancer cells are usually not glucose 
avid. In contrast, radiolabeled choline derivatives (eg, carbon 
11 [11C] and 18F choline) that are used to detect increased cell 
membrane turnover are effective prostate cancer PET tracers. 
In a meta-analysis of 609 patients, the sensitivity and specific-
ity of 11C and 18F choline PET/CT for pelvic lymph node me-
tastases were 62% and 92%, respectively (Fig 4) (26). Another 
ceral metastases and unusual sites of metastatic involvement 
become more frequent. Both CT and bone scanning have 
limited ability to depict the heterogeneity of response behav-
ior of metastatic and local disease, thereby contributing to 
therapy failure and poor patient outcome (15). Hence, there 
is growing interest in next-generation imaging techniques, 
such as whole-body MRI and PET/CT and PET/MRI using 
a variety of radiopharmaceuticals (Table), to improve disease 
assessment. The proposed roles of imaging in the manage-
ment of advanced prostate cancer are summarized in Table E1 
(online). The table shows that in patients with advancing dis-
ease, there are multiple key clinical issues that can be affected 
by imaging. These include identifying the presence and extent 
of metastases, assessing treatment response, and potentially 
providing predictive and prognostic biomarkers for therapy 
selections and allowing identification of metastases that can 
be biopsied for genomic or molecular categorization.
Detection of Metastatic Nodal Disease
Conventional CT imaging.—The performance of conven-
tional CT in the detection of lymph node involvement based 
on size criteria is poor (16) since there is significant overlap in 
the size of benign reactive and metastatic lymph nodes. On 
the basis of size, the diagnostic sensitivity of CT (and conven-
tional anatomic T1- or T2-weighted MRI) sequences in the 
detection of nodal metastases (0.5–2 cm in shorter axis) is less 
than 40% in patients with prostate cancer (16,17) because of 
the high prevalence of micrometastases. For this reason, the 
decision to perform nodal dissection during primary pros-
Figure 1: Schematic shows patient and imaging pathways for disease staging. Recommen-
dations are based on National Comprehensive Cancer Network (NCCN) guidelines, version 
3.2018, and European Association of Urology, European Society for Radiotherapy and Oncol-
ogy, and International Society of Geriatric Oncology (EAU-ESTRO-SIOG) guidelines 2017.
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Summary of the Targets, Strengths, and Weaknesses of PET/CT and PET/MRI Radiopharmaceuticals Widely Used to 
Assess Advanced Prostate Cancer
Radiopharmaceutical Target Strength Weakness
18F FDG Glucose metabolism Tracer activity may identify  
 highly aggressive tumors
Poor performance in  
  prostate cancer, prostate  
cancer cells are usually not  
glucose avid
11C and 18F choline Cell membrane turnover Can be used to visualize  
  both soft-tissue and bone  
disease
Limited sensitivity for liver  
  metastases detection because  
of high tracer uptake in the  
normal liver
68Ga PSMA Cell membrane protein  
  expressed in prostate  
cancer
High sensitivity in the  
  detection of nodal disease,  
promising detection rates  
in prostate cancer with low  
PSA or PSA doubling time
Limited evidence from literature 
  on real impact on patient  
survival, PSMA expression is  
increased with antiandrogen  
therapy
18F NaF Bone turnover High sensitivity for bone  
 metastases detection
Bone disease specific, cannot  
  be used to assess soft-tissue  
disease
18F FDHT Binds to the androgen receptor Indicator of wild-type  
  androgen receptor expression,  
may be useful as a response  
indicator to androgen  
deprivation therapy
Lack of ligand binding due  
  to generation of androgen  
receptor splice variants when  
prostate cancer develops  
resistance to androgen  
deprivation therapy
Note.—FDG = flurodeoxyglucose, FDHT = fluorodihyrotestosterone, PSMA = prostate-specific membrane antigen, NaF = sodium fluoride.
Figure 2: Schematic shows patient and imaging pathways for follow-up. Recommendations are based on National Com-
prehensive Cancer Network (NCCN) guidelines, version 3.2018, and European Association of Urology, European Society for 
Radiotherapy and Oncology, and International Society of Geriatric Oncology (EAU-ESTRO-SIOG) guidelines 2017.
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Figure 3: Ultrasmall superparamagnetic iron oxide (USPIO) MRI was used to detect nodal disease in a 65-year-old 
man with prostate cancer. (a, b) Axial T2*-weighted MRI (multi-echo data image combination, or MEDIC) before (a) 
and after (b) USPIO administration (intravenous feuromoxtran, 0.13 mL per kilogram of body weight) shows normal 
nodal contrast material uptake in normal external iliac lymph nodes (arrows), with reduced nodal signal after contrast 
material administration. On the other hand, a malignant left obturator node (arrowhead) shows no appreciable signal 
reduction after USPIO contrast material administration (Images courtesy of Dr Aslam Sohaib.)
Figure 4: A 63-year-old man with high-risk Gleason 4+3 prostate cancer underwent fluorine 18 (18F) choline PET/MRI to 
detect malignant nodal disease. (a) Coronal T1-weighted PET/MRI shows a 1-cm node (arrow) in the left pelvic sidewall. (b) 
Coronal diffusion-weighted MRI (b value = 900 sec/mm2) shows impeded diffusion (arrow). (c) Coronal fusion 18F choline and 
T1-weighted MRI shows increased tracer activity within the node (arrow), suggesting disease involvement. (Images courtesy of 
Dr Gary Cook.)
meta-analysis by Evangelista et al (27) in 441 patients under-
going nodal staging with 11C and 18F choline PET reported a 
pooled sensitivity of 49.2% and a specificity of 95%. More 
recently, gallium 68 (68Ga) prostate surface membrane antigen 
(PSMA) PET/CT has shown higher sensitivity in the detec-
tion of nodal disease. PSMA is a cell surface enzyme, which is 
overexpressed in patients with prostate cancer. While the name 
suggests that the protein is prostate specific, the protein is also 
expressed by the lacrimal gland, salivary gland, proximal renal 
tubules, small intestine, and neovasculature of the thyroid and 
renal neoplasms (28). In patients with prostate cancer, greater 
PSMA expression is seen with higher Gleason score (29) in 
Advanced Prostate Cancer
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recent data have shown that pelvic radiation therapy, tradition-
ally used in patients without metastases, is also effective in pa-
tients who present with de novo low-volume disease (38).
For these reasons, whole-body MRI, PET/CT, and PET/
MRI are increasingly used to detect bone metastases, with 
frequent upstaging of the oligometastatic state.
MRI.—When compared with bone scanning and CT, MRI is 
more accurate in the detection of bone metastases (35) (Fig 5). 
Whole-body MRI is more sensitive than bone scanning and 
choline PET/CT in the detection of bone metastases on a per-
patient basis, although choline PET/CT showed higher speci-
ficity in one study (35). Modern whole-body MRI comprises 
morphologic sequences (eg, T1- or T2-weighted sequences, 
short inversion time inversion-recovery sequence), and the ad-
dition of DW MRI further improves bone metastasis detection 
(39–41). Whole-body MRI, including DW MRI, has been 
shown to be more sensitive and specific than bone scanning 
in the detection of bone metastases in clinical practice (42), 
although one recent study showed higher diagnostic perfor-
mance with 68Ga PSMA (43). Advantages of using a whole-
body MRI protocol that comprises both conventional and 
DW imaging sequences include high detection sensitivity and 
a more consistent response assessment of bone and visceral 
metastases through use of the standardized METastasis Re-
porting and Data System for Prostate Cancer (MET-RADS-
P) (44,45). MET-RADS-P recommends standardization of 
image acquisition and data collection and facilitates detailed 
recording of the presence, location, and extent of disease. In 
addition, these techniques are widely available and can be 
implemented on standard MRI systems. Whole-body MRI, 
including multiparametric MRI of the prostate, may enable 
one-modality imaging in patients suspected of having pros-
tate cancer relapse (46) and for primary staging in patients 
with high risk (40).
PET/CT and PET/MRI.—PET/CT with 18F sodium fluoride 
(NaF) PET, a bone turnover–specific agent, has higher sensi-
tivity in bone metastases detection compared with planar or 
SPECT bone scanning (47). However, unlike choline PET/
CT, NaF does not accumulate in individuals with nonskeletal 
disease, and it is less cost-effective than bone scanning; how-
ever, it does share the limitations of reduced specificity in the 
differentiation of malignant from benign osteoblastic uptake.
It is unclear whether choline PET/CT is more sensitive 
than conventional bone scanning, but it does have higher 
specificity, with fewer indeterminate bone lesions (26). Won-
dergem et al (48) found choline PET/CT had better specific-
ity than NaF PET/CT in the detection of bone metastases. At 
lesion-based analysis, sensitivity and specificity were 84.0% 
and 97.7%, respectively, with similar results at patient-based 
analysis (85.2% and 96.5%, respectively). There is limited ev-
idence regarding the performance of 68Ga PSMA PET/CT in 
the detection of prostate cancer bone metastasis at initial di-
agnosis. The largest study comparing 68Ga PSMA PET/CT or 
PET/MRI with bone scanning in 37 patients showed 100% 
sensitivity for 68Ga PSMA PET/CT and 57% sensitivity for 
castration-resistant tumors and with androgen deprivation 
therapy (30). In a meta-analysis of five retrospective studies 
with pathology-proven disease, 68Ga PMSA had combined 
sensitivities and specificities of 86% (95% confidence interval: 
37%, 98%) and 86% (95% confidence interval: 3%, 100%), 
respectively, at a patient level (31). In a study of 130 patients 
at high risk for prostate cancer with histopathologic correlation 
(32), 68Ga PSMA PET had a sensitivity of 65.9%. The mean 
size of malignant nodes missed with 68Ga PSMA PET was 3 
mm 6 1 (standard deviation). More recently, second-gener-
ation 18F-labeled PSMA-directed radiopharmaceuticals with 
longer half-life, slightly different biodistribution and kinetics, 
and higher spatial resolution than 68Ga have shown promise for 
disease staging and biochemical relapse (33). The 18F PSMA 
can depict metastases in nodes smaller than 8 mm in diameter 
(34), but additional studies are needed to establish the clinical 
utility of 18F PSMA tracers.
Detection of Bone Metastases
Standard bone scan and CT.—Technetium 99m (99mTc) di-
phosphonate bone scanning is the most widely used method 
to evaluate bone metastasis presence in patients with prostate 
cancer. Bone matrix interactions are depicted (osteoblastic 
activity and increased bone turnover in the vicinity of the 
metastases). However, early metastases confined to the bone 
marrow may not show tracer uptake, thereby limiting disease 
detection. The addition of SPECT to planar imaging, espe-
cially when using hybrid SPECT/CT cameras, can improve 
diagnostic accuracy by reducing the number of equivocal 
lesions and allows more direct comparison with CT and 
MRI. A meta-analysis of 1102 patients with prostate can-
cer comprising 12 studies using 99 mTc planar bone scanning 
and three studies using SPECT showed a combined sensitiv-
ity and specificity for bone metastasis detection of 79% and 
82%, respectively, on a per-patient basis. On a per-lesion ba-
sis, diagnostic sensitivity and specificity were 59% and 75%, 
respectively, for planar bone scanning compared with 90% 
and 85%, respectively, with the addition of SPECT (35).
CT has modest diagnostic accuracy in the detection of 
bone metastases. This is because small lesions within the bone 
marrow are difficult to distinguish from the fatty marrow, and 
substantial bone destruction or new bone formation must oc-
cur before lesions can be detected. The pooled sensitivity and 
specificity of CT in the detection of bone metastases from 
prostate tumors and other tumor types are reportedly 73% 
and 95%, respectively (36). However, like many studies re-
porting on the accuracy of bone scanning, these were con-
ducted without pathologic analysis as the reference standard 
and in patients with advanced disease, which can bias results 
toward better diagnostic performance.
In recognition of the fact that both bone scanning (37) and 
CT (36) result in underestimation of the presence and extent 
of bone disease, there are implications for patient care, as treat-
ment is increasingly stratified according to disease presence 
and extent, particularly in patients with oligometastatic dis-
ease who frequently receive focal treatments (10). Additionally, 
Perez-Lopez et al
Radiology: Volume 292: Number 2—August 2019  n  radiology.rsna.org 279
The main published meta-analyses and prospective imaging 
studies of radiopharmaceuticals and MRI in nodal and bone me-
tastases assessment are summarized in Tables E2 and E3 (online).
Oligometastatic Prostate Cancer at Initial 
Staging and Disease Relapse: Changing 
Paradigm
The improved performance of prostate cancer–directed next-
generation imaging methods (54,55) in the detection of 
small-volume metastases has enhanced interest in treatment 
of the oligometastatic state. Oligometastatic disease may be 
an earlier intermediate stage in cancer spread in between lo-
calized disease and widespread metastases. Oligometastatic 
disease has been defined as no more than five detectable me-
tastases in three clinical scenarios: de novo oligometastatic 
prostate cancer, oligorecurrent prostate cancer (Fig 7), and 
oligoprogressive prostate cancer (10,11). Focal treatments, 
such as radiation therapy or surgery, have been postulated 
to debulk metastatic tumor and slow disease progression, 
perhaps delaying the start of systemic treatment (10,11,56). 
Others, however, have expressed skepticism (57), comment-
ing that the oligometastatic state is merely a feature of limited 
sensitivity in disease detection (58). Nonetheless, randomized 
controlled trials are now being conducted to address unan-
swered questions regarding the treatment of oligometastases 
and metastases-directed therapies (11) and the role of ad-
vanced imaging in this disease setting.
bone scanning; specificity was comparable (100% vs 96%, re-
spectively) (49) (Fig 6), bearing in mind the caveat of absent 
lesion-based histologic verification.
Other Radiopharmaceuticals to Detect Disease in 
Advanced Prostate Cancer
The radioconjugate containing a derivative of testosterone, 16-b-
fluoro-5-a-dihydrotestosterone (FDHT), and labeled with 18F 
(18F FDHT) binds to the androgen receptor. In patients with 
CRPC, 18F FDHT PET/CT has reasonable sensitivity (86%) in 
disease detection (50) and as an indicator of wild-type androgen 
receptor expression. It may also indicate response to antiandro-
genic drugs (51). However, advancing prostate cancers acquire 
antiandrogen treatment resistance, with the emergence of andro-
gen-receptor splice variants lacking the ligand binding domain, 
which can limit the usefulness of this agent.
As prostate cancers upregulate certain amino acid transport-
ers, anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid, 
or FACBC, also known as 18F fluciclovine, is an amino acid analog 
directed at fatty acid synthesis that has been evaluated as an 
imaging tracer. A meta-analysis of 251 patients showed pooled 
sensitivity and specificity of 87% and 66%, respectively (52). 
Another multicenter study in 596 patients showed sensitiv-
ity and specificity of 62.7% and 69.9%, respectively, in the 
detection of disease relapse (53), which may lead to false-
positive results and spurious upstaging of disease because of 
the lower diagnostic specificity.
Figure 5: Whole-body MRI has higher sensitivity for bone metastases detection in a 71-year-old man with castration-resistant 
prostate cancer who was receiving antiandrogen targeted therapy and had a rising prostate-specific antigen (PSA) level (109 
ng/mL) and a PSA doubling time of 1.5 months. (a) Coronal anterior (left) and posterior (right) images obtained with techne-
tium 99m bone scintigraphy. (b) Inverted coronal maximum intensity projection whole-body diffusion-weighted (DW) MRI (b 
value = 900 sec/mm2) shows marked discrepancy between the number of metastatic bone lesions detected, with whole-body 
DW MRI showing more bone disease as multiple low-signal-intensity focal lesions.
Advanced Prostate Cancer
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because of disease molecular heterogeneity, such that radio-
logic progression can occur without an increase in PSA level 
(63) (Fig 8). Thus, imaging is becoming more important in 
the assessment of treatment benefit in patients with meta-
static CRPC. A major challenge remains the lack of objective 
criteria to assess response of disease confined to the bone mar-
row, which is common in individuals with advanced prostate 
cancer (13,14).
Assessment of Soft-Tissue Disease Response
Prostate Cancer Working Group 3 criteria include the Re-
sponse Evaluation Criteria in Solid Tumors (RECIST), version 
1.1, applied to conventional CT and MRI to assess the treat-
ment response of soft-tissue disease in patients with advanced 
Published data from choline PET/CT (11) and whole-
body MRI (55) show that patients with oligometastatis expe-
rience relapse most often in the nodes, followed by relapse in 
bone and viscera. While this finding is encouraging, there is 
a lack of conclusive evidence on the use of PET/CT or PET/
MRI with new prostate cancer–directed radiopharmaceuticals 
in the management of oligometastatic disease (20,59–61).
Detection of Therapeutic Response
The availability of several effective therapies for advanced 
prostate cancer has shifted the treatment paradigm toward 
a more aggressive approach. Overall, measurement of serum 
PSA level alone to monitor treatment response is not recom-
mended (62), especially in patients with metastatic CRPC 
Figure 6: Gallium 68 (68Ga) PET targeting the prostate-specific membrane antigen (PSMA) enables 
detection of bone metastases not visible at bone scanning in a 100-year-old man with castration-resistant 
prostate cancer, a rising serum prostate-specific antigen (PSA) level (81 ng/mL), and a PSA doubling time 
of 2.7 months. (a) Coronal anterior (left) and posterior (right) images obtained with technetium 99m scin-
tigraphy. (b) Coronal unenhanced CT and (c) 68Ga PSMA images show a false-negative result. All images 
were acquired within 1 month of each other. In c, there is a PSMA-avid left anterior iliac crest bone metas-
tasis (arrow) not visible on a or b, which prompted antiandrogen targeted therapy.
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is unable to define new bone lesions in patients with diffuse 
bone involvement. (c) Bone scanning must be repeated 6–12 
weeks after the first bone scan to confirm disease progression, 
thereby prolonging patient exposure to the toxicities of non-
efficacious treatment. (d) Enlargement of bone lesions does 
not qualify as a progression criterion. (e) The Prostate Cancer 
Working Group 3 criteria document bone disease progres-
sion but have no direct measure of treatment benefit. Nev-
ertheless, this method of defining radiographic progression-
free survival for bone disease, in combination with modified 
RECIST, version 1.1, for soft-tissue disease, has been shown 
to correlate with overall disease survival (64) and is widely 
adopted in clinical trials.
The bone scan index is a semiquantitative index. It is a 
method of expressing the tumor burden in bone as a percent-
age of total skeletal mass. The bone scan index can facilitate 
comparison of results across measurement time points and 
institutions. Studies have shown that the bone scan index is 
prognostic, both at baseline (65) and at follow-up, with pa-
tients who have a smaller increase in bone scan index during 
treatment having longer overall survival (66). However, the 
bone scan index still does not overcome the issue of flare phe-
nomenon, nor can it enable direct assessment of treatment 
benefit.
Radiopharmaceuticals for PET imaging.—Interesting re-
sults are emerging from small studies in which PET/CT or 
PET/MRI were used with different radiopharmaceuticals. 18F 
NaF PET/CT has shown good measurement variability with 
coefficients of variation for maximum (14.1%) and mean 
(6.6%) standardized uptake values (SUVs) (67). Harmon et 
al (68) found that patients who showed disease progression at 
18F NaF PET/CT by measuring the functional SUV disease 
burden have shorter progression-free survival. However, simi-
lar to bone scanning, the flare response (ie, increased tracer 
activity related to treatment) may confound assessments. 
Likewise, 18F NaF PET/CT appears to be more useful in the 
detection of disease progression, as there are no universally 
accepted response criteria, and the technique is not used to 
assess soft-tissue disease.
PET/CT with choline radiolabeled with either 18F or 11C 
and PSMA radiolabeled with either 68Ga or 18F has the ad-
vantage of enabling one to assess soft-tissue disease and bone 
disease at the same time. Several studies have also shown that 
18F choline PET/CT can depict disease progression earlier 
than conventional CT and bone scanning. Decreases in SUV 
correlate with overall survival (69–71). Flare response may 
also be observed early after the start of therapy (69). A poten-
tial limitation of choline PET/CT is the poor visualization of 
liver metastases due to high normal liver background tracer 
uptake.
A recent study assessed bone response to chemotherapy 
with 68Ga PSMA PET/CT (72). Inhibition of the androgen 
receptor (eg, by androgen deprivation therapy drug treat-
ment) can markedly increase PSMA expression (73). This can 
limit the usefulness of this technique in monitoring the thera-
peutic effects of androgen deprivation therapy.
prostate cancer. This relies on accurate measurements of sum-
mated tumor diameters to categorize therapeutic effects. In the 
clinical trial setting, whole-body MRI, as well as PET/CT and 
PET/MRI with a range of radiopharmaceuticals, are investi-
gated for treatment response assessment in patients with soft-
tissue and bone disease. These are discussed in the next section.
Assessing Response of Bone Metastases
Radionuclide bone scan.—When evaluating therapeutic 
benefits in bone metastases, bone scanning is widely used as 
part of the validated Prostate Cancer Working Group 3 cri-
teria (51) to determine disease progression after treatment. 
These criteria require identification of at least two new bone 
lesions in consecutive bone scans performed 9–12 weeks 
apart; if detected, the new bone lesions need to be confirmed 
with a subsequent bone scan performed a minimum of 6 
weeks later to confirm progression. This is because the os-
teoblastic flare phenomenon may occur during bone healing 
(Fig 9) (51). Identification of new lesions is suboptimal in 
patients with diffuse disease showing generalized increased 
tracer uptake.
These criteria have substantial limitations given recent im-
aging advances. (a) There is a reliance on bone scanning to 
depict new metastases, and this modality is less sensitive than 
PET/CT, PET/MRI, or whole-body MRI. (b) Bone scanning 
Figure 7: Gallium 68 (68Ga) PET targeting the prostate-specific 
membrane antigen (PSMA) enables detection of oligorecurrent rib 
metastasis in a 73-year-old patient with castration-resistant prostate 
cancer 3 years after initiation of androgen deprivation therapy. (a, 
b) Axial unenhanced CT (a) and 68Ga PSMA PET (b) images show 
a solitary site of recurrence (arrow) in the right fourth rib on b that is 
difficult to discern on a. Surgical rib resection enabled confirmation of 
metastatic prostate cancer. The serum prostate-specific antigen level 
became undetectable after surgery.
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PSMA ligand-directed treatments, such as radioimmunocon-
jugates or immunoconjugates with cytotoxic payloads (78). A 
number of tracers can be linked for diagnostic (eg, 18F, 68Ga, 
and 89Zr) or therapeutic (eg, 131I, 177Lu, 225Ac) indications.
The PSMA-targeting theranostic concept offers a new 
treatment option in patients with CRPC when the ligand is 
labeled with b-emitting 177Lu or 131I isotopes or an a-emit-
ting 225Ac isotope (79). There is compelling evidence that 
177Lu PSMA-617 can lead to a biochemical response (serum 
PSA reduction of .50%) (80) and improved progression-free 
survival with relatively low incidence of adverse side-effects 
in patients with advanced prostate cancer (79,81). A recent 
meta-analysis of 10 studies comprising 455 patients found 
that serum PSA decline was observed in 68% of patients after 
Whole-body MRI (including DW MRI).—DW 
MRI is a technique that does not require intra-
venous contrast material injection and provides 
insight into tumor cellularity and tumor cell 
kill. By combining anatomic and functional 
imaging, whole-body DW MRI can be used to 
assess tumor response without the confounder 
of flare phenomenon. Whole-body DW MRI 
can also depict complications, such as malig-
nant spinal cord compression, fractures, or 
genitourinary tract obstructions. Evidence is 
accumulating for the value of whole-body DW 
MRI in the assessment of therapeutic response 
(74–76). Two quantitative parameters derived 
from whole-body DW MRI—apparent dif-
fusion coefficient value and tumor diffusion 
volume—have been shown to correlate with 
circulating biomarkers and clinical response to 
olaparib (an inhibitor of the enzyme poly [ADP-
ribose] polymerase, also known as a PARP in-
hibitor) in individuals with advanced prostate 
cancer (Fig 10) (74). The re-
cently published MET-RADS-P 
criteria (44) combine RECIST version 1.1 
for soft-tissue assessment with new DW 
MRI bone metastases response criteria. 
MET-RADS-P reporting criteria also facilitate 
the categorization of response to treatment, 
including any discordant or heterogeneous re-
sponses. Application of MET-RADS-P criteria 
could facilitate the conduct of multicenter clini-
cal trials using whole-body MRI to define better 
response criteria in patients with bone disease.
Circulating tumor cells.—Concerted efforts 
are being made to standardize blood circulating 
tumor cell count as a treatment response crite-
rion. The results from 6081 patients in five pro-
spective randomized phase III trials for blood 
circulating tumor cell count have been recently 
reported (77). Changes in circulating tumor cell 
count measurement before treatment and 13 
weeks after treatment were robust and meaningful response 
end points for early phase metastatic CRPC trials. However, 
many patients have low circulating tumor cell counts despite 
having widespread disease. This suggests heterogeneity in the 
shedding of tumor cells into the blood or the sensitivity of the 
assay for their detection.
Theranostics: Diagnosing and Treating 
Advanced Prostate Cancer with 
Radiopharmaceuticals
Theranostic imaging refers to the combination of an imag-
ing biomarker and a specific targeted therapy with radiophar-
maceuticals. The overexpression of PSMA in patients with 
CRPC has led to the development of PSMA PET/CT trac-
ers as a potential imaging biomarker to guide therapy using 
Figure 8: Discordant radiologic and biochemical response in a 68-year-old man 
with metastatic castration-resistant prostate cancer who had undergone previous 
treatment with pelvic exenteration for locally advanced prostate cancer and was 
currently on antiandrogen targeted therapy. Inverted gray-scale coronal maximum 
intensity projection whole-body diffusion-weighted MRI (b value = 900 sec/mm2) 
obtained (a) before and (b) at 12 weeks of treatment shows an increase in the num-
ber of bone metastases (color overlay in red), with a contemporaneous reduction in 
serum prostate-specific antigen (PSA) level from 16 to 4.8 ng/mL. Progression was 
confirmed 8 weeks later when new bone lesions were seen on a bone scan obtained 
by using Prostate Cancer Working Group 3 criteria and when new lung metastases 
were seen on a CT scan (not shown), while the serum PSA level remained low.
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tumor burden that has prognostic implications, (c) manage-
ment of oligometastatic disease, and (d) earlier detection of 
response or progression of bone disease to therapy.
In addition, there are opportunities to use novel imaging 
to advance knowledge of evolving tumor biology. Imaging 
can be used to study tumor heterogeneity, both within and 
between tumors. Imaging-targeted tissue sampling will fur-
ther our understanding of the molecular and genetic profiles 
associated with treatment resistance, thus guiding therapy se-
lection. The use of PET radiopharmaceuticals, such as PSMA 
and FDHT, can provide insights into receptor expression and 
signaling pathways, which may indicate sensitivity or resis-
tance to treatments and can guide the development of future 
theranostics.
Robust quantitative measurements across imaging plat-
forms are achievable with whole-body DW MRI, as apparent 
diffusion coefficient measurements have been shown to have 
good measurement repeatability and reproducibility. How-
ever, more studies are needed to validate whole-body MRI 
measurements as response, predictive, or prognostic bio-
markers, including the performance of standardized report-
ing systems (eg, MET-RADS-P) in the clinical setting. The 
cost-effectiveness of these modern imaging techniques is also 
yet to be determined.
Regionally limited availability of novel imaging tracers and 
the variable imaging expertise across centers constitute major 
impediments toward the development of validated imaging 
treatment, with 34% of patients showing a PSA decline of 
more than 50%. The pooled hazard ratios for the overall sur-
vival of any PSA decline was 0.29 (P , .001), indicating se-
rum PSA decrease was associated with longer overall survival 
(82). The incidence of hematologic toxicity (grade III or IV) 
was reportedly low, comprising anemia (9%), thrombocyto-
penia (4%), and neutropenia (6%) (83). More recently, it was 
shown that disease SUV at 68Ga-PSMA PET imaging at base-
line screening was predictive of a more than 30% reduction 
in the serum PSA level (84) after 177Lu PSMA-617 therapy. In 
addition, a decrease in segmented total tumor volume at 68Ga 
PSMA PET imaging was associated with serum PSA response 
after 177Lu PSMA therapy (85). The presence of hepatic dis-
ease in patients was associated with poorer serum PSA re-
sponse, as well as shorter progression-free and overall survival 
(83). However, the long-term outcomes and efficacy of 177Lu 
PSMA treatment need to be further validated in prospective 
clinical trials.
Potential and Challenges of Next-
Generation Imaging
There is substantial promise in the use of next-generation im-
aging to aid the delivery of precision oncology in patients 
with advanced prostate cancer. Areas in which the greatest 
potential impact may be seen include (a) early and timely 
detection of biochemical recurrence that may increase the 
chances of cure, (b) more accurate depiction of metastatic 
Figure 9: Flare phenomenon was seen on technetium 99m (99mTc) bone scans 12 weeks after successful therapy in a 64-year-old man with met-
astatic castration-resistant prostate cancer with bone-only metastases. (a–c) Coronal anterior (left) and posterior (right) 99mTc bone scans obtained 
at baseline (a), 12 weeks (b), and 24 weeks (c) after therapy. Note the multiple new rib metastases in b, with no further new bone lesions in c. 
When the Prostate Cancer Working Group 3 criteria were applied, the criteria for disease progression were not met, and flare phenomenon was 
documented. A contemporaneous serum prostate-specific antigen response was observed, with 61% reduction at 12 weeks and 69% reduction at 
24 weeks.
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and use of precision therapies in patients with advanced pros-
tate cancer, with the aim of improving outcome.
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criteria. Furthermore, different classes of drugs used to treat 
metastatic CRPC may impact imaging in unique ways that 
are relatively underexplored. Some drug, such as abiraterone 
or enzalutamide, may change the regulation of the targets for 
radiopharmaceuticals without killing cancer cells, and such 
potential effects need to be better understood when selecting 
modern imaging for treatment response assessment.
In conclusion, next-generation imaging techniques will 
undoubtedly play increasing roles in defining the presence 
and extent of metastatic disease and enabling assessment 
of treatment response and disease progression, particularly 
in patients with bone disease, and will improve our under-
standing of disease biology through imaging-targeted tumor 
sampling. These developments will promote the development 
Figure 10: Whole-body MRI shows a response to a targeted therapy (poly [ADP-ribose] polymerase inhibitor). (a, 
b) Images of inverted gray-scale coronal maximum intensity projection (MIP) whole-body diffusion-weighted [DW] MRI 
(b value = 900 sec/mm2) before (a) and 12 weeks after (b) treatment in a 70-year-old man with castration-resistant 
prostate cancer. Color overlay in red shows projection of disease sites before (a) and after (b) treatment, which are sum-
mated to derive the total diffusion volume (tDV, from DW imaging [b = 900 sec/mm2] disease signal) and the associ-
ated global apparent diffusion coefficient (ADC) values, as shown in (c) the histograms (plotted as probability density on 
the y axis). The images show dramatic reduction in tDV (from 613 mL to 54 mL) accompanied by a marked regression 
of lung, liver, and nodal metastases, as well as the local prostate tumor. However, there is heterogeneous response, 
with persistent signal abnormality in the left pelvic bone and the left lung on MIP images. (d) Axial posttreatment ADC 
map through the pelvis shows responding disease (color coded green, ADC . 1.3 µm2/sec) is visible in the anterior left 
acetabulum, while nonresponding disease (color coded red, ADC = 0.73 µm2/sec) is seen in the posterior left acetabu-
lum, accounting for the bimodal distribution of the posttreatment global ADC histogram.
Perez-Lopez et al
Radiology: Volume 292: Number 2—August 2019  n  radiology.rsna.org 285
in normal-sized nodes of bladder and prostate cancer patients. Eur Urol 
2009;55(4):761–769.
 24. Woo S, Suh CH, Kim SY, Cho JY, Kim SH. The diagnostic performance 
of MRI for detection of lymph node metastasis in bladder and prostate 
cancer: an updated systematic review and diagnostic meta-analysis. AJR Am 
J Roentgenol 2018;210(3):W95–W109.
 25. Salminen E, Hogg A, Binns D, Frydenberg M, Hicks R. Investigations with 
FDG-PET scanning in prostate cancer show limited value for clinical practice. 
Acta Oncol 2002;41(5):425–429.
 26. von Eyben FE, Kairemo K. Meta-analysis of (11)C-choline and (18)F-choline 
PET/CT for management of patients with prostate cancer. Nucl Med Com-
mun 2014;35(3):221–230.
 27. Evangelista L, Guttilla A, Zattoni F, Muzzio PC, Zattoni F. Utility of cho-
line positron emission tomography/computed tomography for lymph node 
involvement identification in intermediate- to high-risk prostate cancer: a sys-
tematic literature review and meta-analysis. Eur Urol 2013;63(6):1040–1048.
 28. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-
specific membrane antigen expression in normal and malignant human 
tissues. Clin Cancer Res 1997;3(1):81–85.
 29. Bravaccini S, Puccetti M, Bocchini M, et al. PSMA expression: a potential 
ally for the pathologist in prostate cancer diagnosis. Sci Rep 2018;8(1):4254.
 30. Bakht MK, Oh SW, Youn H, Cheon GJ, Kwak C, Kang KW. Influence of an-
drogen deprivation therapy on the uptake of PSMA-targeted agents: emerging 
opportunities and challenges. Nucl Med Mol Imaging 2017;51(3):202–211.
 31. Perera M, Papa N, Christidis D, et al. Sensitivity, specificity, and predictors 
of positive 68Ga-prostate-specific membrane antigen positron emission to-
mography in advanced prostate cancer: a systematic review and meta-analysis. 
Eur Urol 2016;70(6):926–937.
 32. Maurer T, Gschwend JE, Rauscher I, et al. Diagnostic efficacy of (68)gallium-
PSMA positron emission tomography compared to conventional imaging for 
lymph node staging of 130 consecutive patients with intermediate to high 
risk prostate cancer. J Urol 2016;195(5):1436–1443.
 33. Giesel FL, Knorr K, Spohn F, et al. Detection efficacy of [18F]PSMA-1007 
PET/CT in 251 Patients with biochemical recurrence after radical prostatec-
tomy. J Nucl Med 2018 Jul 24 [Epub ahead of print] https://doi.org/10.2967/
jnumed.118.212233.
 34. Giesel FL, Will L, Kesch C, et al. Biochemical recurrence of prostate cancer: 
initial results with [18F]PSMA-1007 PET/CT. J Nucl Med 2018;59(4):632–635.
 35. Shen G, Deng H, Hu S, Jia Z. Comparison of choline-PET/CT, MRI, SPECT, 
and bone scintigraphy in the diagnosis of bone metastases in patients with 
prostate cancer: a meta-analysis. Skeletal Radiol 2014;43(11):1503–1513.
 36. Yang HL, Liu T, Wang XM, Xu Y, Deng SM. Diagnosis of bone metastases: 
a meta-analysis comparing ¹⁸FDG PET, CT, MRI and bone scintigraphy. 
Eur Radiol 2011;21(12):2604–2617.
 37. Lecouvet FE, Geukens D, Stainier A, et al. Magnetic resonance imaging of 
the axial skeleton for detecting bone metastases in patients with high-risk 
prostate cancer: diagnostic and cost-effectiveness and comparison with current 
detection strategies. J Clin Oncol 2007;25(22):3281–3287.
 38. Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary 
tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a 
randomised controlled phase 3 trial. Lancet 2018;392(10162):2353–2366.
 39. Jambor I, Kuisma A, Ramadan S, et al. Prospective evaluation of planar 
bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole 
body 1.5T MRI, including DWI, for the detection of bone metastases in 
high risk breast and prostate cancer patients: SKELETA clinical trial. Acta 
Oncol 2016;55(1):59–67.
 40. Lecouvet FE, El Mouedden J, Collette L, et al. Can whole-body mag-
netic resonance imaging with diffusion-weighted imaging replace Tc 
99m bone scanning and computed tomography for single-step detec-
tion of metastases in patients with high-risk prostate cancer? Eur Urol 
2012;62(1):68–75.
 41. Gutzeit A, Doert A, Froehlich JM, et al. Comparison of diffusion-weighted 
whole body MRI and skeletal scintigraphy for the detection of bone 
metastases in patients with prostate or breast carcinoma. Skeletal Radiol 
2010;39(4):333–343.
 42. Pasoglou V, Larbi A, Collette L, et al. One-step TNM staging of 
high-risk prostate cancer using magnetic resonance imaging (MRI): 
toward an upfront simplified “all-in-one” imaging approach? Prostate 
2014;74(5):469–477.
 43. Dyrberg E, Hendel HW, Huynh THV, et al. 68Ga-PSMA-PET/CT in com-
parison with 18F-fluoride-PET/CT and whole-body MRI for the detection 
of bone metastases in patients with prostate cancer: a prospective diagnostic 
accuracy study. Eur Radiol 2019;29(3):1221–1230.
 44. Padhani AR, Lecouvet FE, Tunariu N, et al. METastasis Reporting and 
Data System for Prostate Cancer: practical guidelines for acquisition, inter-
pretation, and reporting of whole-body magnetic resonance imaging-based 
disclosed no relevant relationships. M.J.M. Activities related to the present article: 
received a consulting fee from Advanced Accelerator Applications; received support 
for travel from Endocyte, Bayer, and Progenics. Activities not related to the present 
article: received research funding from Bayer, Progenics, Corcept, Endocyte, Sanofi, 
and Janssen. Other relationships: disclosed no relevant relationships. J.d.B. disclosed 
no relevant relationships. D.M.K. Activities related to the present article: disclosed 
no relevant relationships. Activities not related to the present article: is on the Bayer 
Healthcare Speakers Bureau. Other relationships: disclosed no relevant relationships.
References
 1. Cronin KA, Lake AJ, Scott S, et al. Annual report to the nation on the status 
of cancer, part I: national cancer statistics. Cancer 2018;124(13):2785–2800.
 2. Wei L, Wang J, Lampert E, et al. Intratumoral and intertumoral genomic 
heterogeneity of multifocal localized prostate cancer impacts molecular clas-
sifications and genomic prognosticators. Eur Urol 2017;71(2):183–192.
 3. Wadosky KM, Koochekpour S. Androgen receptor splice variants and prostate 
cancer: from bench to bedside. Oncotarget 2017;8(11):18550–18576.
 4. Jamaspishvili T, Berman DM, Ross AE, et al. Clinical implications of PTEN 
loss in prostate cancer. Nat Rev Urol 2018;15(4):222–234.
 5. Taylor RA, Fraser M, Livingstone J, et al. Germline BRCA2 mutations 
drive prostate cancers with distinct evolutionary trajectories. Nat Commun 
2017;8:13671.
 6. Mateo J, Carreira S, Sandhu S, et al. DNA-repair defects and olaparib in 
metastatic prostate cancer. N Engl J Med 2015;373(18):1697–1708.
 7. Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of 
advanced prostate cancer. Cell 2015;162(2):454.
 8. National Comprehensive Cancer Network. NCCN Guidelines Version 
3.2018: Prostate Cancer. https://www.nccn.org/professionals/physician_gls/
pdf/prostate.pdf. Published 2018. Accessed December 1, 2018.
 9. Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on 
prostate cancer. Part 1: screening, diagnosis, and local treatment with curative 
intent. Eur Urol 2017;71(4):618–629.
 10. Tosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaeffer EM. Oligo-
metastatic prostate cancer: definitions, clinical outcomes, and treatment 
considerations. Nat Rev Urol 2017;14(1):15–25.
 11. De Bleser E, Tran PT, Ost P. Radiotherapy as metastasis-directed therapy 
for oligometastatic prostate cancer. Curr Opin Urol 2017;27(6):587–595.
 12. Mateo J, Fizazi K, Gillessen S, et al. Managing nonmetastatic castration-
resistant prostate cancer. Eur Urol 2019;75(2):285–293.
 13. James ND, Spears MR, Clarke NW, et al. Survival with newly diagnosed 
metastatic prostate cancer in the “docetaxel era”: data from 917 patients in 
the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). 
Eur Urol 2015;67(6):1028–1038.
 14. Halabi S, Kelly WK, Ma H, et al. Meta-analysis evaluating the impact of 
site of metastasis on overall survival in men with castration-resistant prostate 
cancer. J Clin Oncol 2016;34(14):1652–1659.
 15. Spratt DE, Zumsteg ZS, Feng FY, Tomlins SA. Translational and clinical 
implications of the genetic landscape of prostate cancer. Nat Rev Clin Oncol 
2016;13(10):597–610.
 16. Hövels AM, Heesakkers RA, Adang EM, et al. The diagnostic accuracy of 
CT and MRI in the staging of pelvic lymph nodes in patients with prostate 
cancer: a meta-analysis. Clin Radiol 2008;63(4):387–395.
 17. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of 
clinically occult lymph-node metastases in prostate cancer. N Engl J Med 
2003;348(25):2491–2499.
 18. Briganti A, Larcher A, Abdollah F, et al. Updated nomogram predicting 
lymph node invasion in patients with prostate cancer undergoing extended 
pelvic lymph node dissection: the essential importance of percentage of 
positive cores. Eur Urol 2012;61(3):480–487.
 19. Gandaglia G, Fossati N, Zaffuto E, et al. Development and internal valida-
tion of a novel model to identify the candidates for extended pelvic lymph 
node dissection in prostate cancer. Eur Urol 2017;72(4):632–640.
 20. Thoeny HC, Barbieri S, Froehlich JM, Turkbey B, Choyke PL. Functional 
and targeted lymph node imaging in prostate cancer: current status and future 
challenges. Radiology 2017;285(3):728–743.
 21. Thoeny HC, Froehlich JM, Triantafyllou M, et al. Metastases in normal-
sized pelvic lymph nodes: detection with diffusion-weighted MR imaging. 
Radiology 2014;273(1):125–135.
 22. Birkhäuser FD, Studer UE, Froehlich JM, et al. Combined ultrasmall 
superparamagnetic particles of iron oxide-enhanced and diffusion-weighted 
magnetic resonance imaging facilitates detection of metastases in normal-sized 
pelvic lymph nodes of patients with bladder and prostate cancer. Eur Urol 
2013;64(6):953–960.
 23. Thoeny HC, Triantafyllou M, Birkhaeuser FD, et al. Combined ultrasmall 
superparamagnetic particles of iron oxide-enhanced and diffusion-weighted 
magnetic resonance imaging reliably detect pelvic lymph node metastases 
Advanced Prostate Cancer
286 radiology.rsna.org  n Radiology: Volume 292: Number 2—August 2019
evaluations of multiorgan involvement in advanced prostate cancer. Eur Urol 
2017;71(1):81–92.
 45. Barnes A, Alonzi R, Blackledge M, et al. UK quantitative WB-DWI technical 
workgroup: consensus meeting recommendations on optimisation, quality 
control, processing and analysis of quantitative whole-body diffusion-weighted 
imaging for cancer. Br J Radiol 2018;91(1081):20170577.
 46. Robertson NL, Sala E, Benz M, et al. Combined whole body and multipa-
rametric prostate magnetic resonance imaging as a 1-step approach to the 
simultaneous assessment of local recurrence and metastatic disease after radical 
prostatectomy. J Urol 2017;198(1):65–70.
 47. Tateishi U, Morita S, Taguri M, et al. A meta-analysis of (18)F-fluoride 
positron emission tomography for assessment of metastatic bone tumor. 
Ann Nucl Med 2010;24(7):523–531.
 48. Wondergem M, van der Zant FM, van der Ploeg T, Knol RJ. A literature 
review of 18F-fluoride PET/CT and 18F-choline or 11C-choline PET/CT 
for detection of bone metastases in patients with prostate cancer. Nucl Med 
Commun 2013;34(10):935–945.
 49. Pyka T, Okamoto S, Dahlbender M, et al. Comparison of bone scintigraphy 
and 68Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med 
Mol Imaging 2016;43(12):2114–2121.
 50. Larson SM, Morris M, Gunther I, et al. Tumor localization of 16beta-18F-
fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progres-
sive, metastatic prostate cancer. J Nucl Med 2004;45(3):366–373.
 51. Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for 
castration-resistant prostate cancer: updated recommendations from the prostate 
cancer clinical trials working group 3. J Clin Oncol 2016;34(12):1402–1418.
 52. Ren J, Yuan L, Wen G, Yang J. The value of anti-1-amino-3-18F-fluorocy-
clobutane-1-carboxylic acid PET/CT in the diagnosis of recurrent prostate 
carcinoma: a meta-analysis. Acta Radiol 2016;57(4):487–493.
 53. Bach-Gansmo T, Nanni C, Nieh PT, et al. Multisite experience of the safety, 
detection rate and diagnostic performance of fluciclovine (18F) positron 
emission tomography/computerized tomography imaging in the staging of 
biochemically recurrent prostate cancer. J Urol 2017;197(3 Pt 1):676–683.
 54. Joice GA, Rowe SP, Pienta KJ, Gorin MA. Oligometastatic prostate cancer: 
shaping the definition with molecular imaging and an improved understand-
ing of tumor biology. Curr Opin Urol 2017;27(6):533–541.
 55. Larbi A, Dallaudière B, Pasoglou V, et al. Whole body MRI (WB-MRI) assess-
ment of metastatic spread in prostate cancer: therapeutic perspectives on targeted 
management of oligometastatic disease. Prostate 2016;76(11):1024–1033.
 56. Ost P, Jereczek-Fossa BA, As NV, et al. Progression-free survival following 
stereotactic body radiotherapy for oligometastatic prostate cancer treatment-
naive recurrence: a multi-institutional analysis. Eur Urol 2016;69(1):9–12.
 57. Murphy DG, Sweeney CJ, Tombal B. “Gotta catch ‘em all”, or do we? 
Pokemet approach to metastatic prostate cancer. Eur Urol 2017;72(1):1–3.
 58. Palma DA, Salama JK, Lo SS, et al. The oligometastatic state: separating 
truth from wishful thinking. Nat Rev Clin Oncol 2014;11(9):549–557.
 59. Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G. 68Ga-labeled 
prostate-specific membrane antigen ligand positron emission tomography/
computed tomography for prostate cancer: a systematic review and meta-
analysis. Eur Urol Focus 2018;4(5):686–693.
 60. Mapelli P, Incerti E, Ceci F, Castellucci P, Fanti S, Picchio M. 11C- or 
18F-choline PET/CT for imaging evaluation of biochemical recurrence of 
prostate cancer. J Nucl Med 2016;57(Suppl 3):43S–48S.
 61. Evangelista L, Zattoni F, Karnes RJ, Novara G, Lowe V. Radiolabeled choline 
PET/CT before salvage lymphadenectomy dissection: a systematic review 
and meta-analysis. Nucl Med Commun 2016;37(12):1223–1231.
 62. Gillessen S, Attard G, Beer TM, et al. Management of patients with advanced 
prostate cancer: the report of the advanced prostate cancer consensus confer-
ence APCCC 2017. Eur Urol 2018;73(2):178–211.
 63. Bryce AH, Alumkal JJ, Armstrong A, et al. Radiographic progression with 
nonrising PSA in metastatic castration-resistant prostate cancer: post hoc 
analysis of PREVAIL. Prostate Cancer Prostatic Dis 2017;20(2):221–227.
 64. Morris MJ, Molina A, Small EJ, et al. Radiographic progression-free survival 
as a response biomarker in metastatic castration-resistant prostate cancer: 
COU-AA-302 results. J Clin Oncol 2015;33(12):1356–1363.
 65. Nakajima K, Edenbrandt L, Mizokami A. Bone scan index: a new bio-
marker of bone metastasis in patients with prostate cancer. Int J Urol 
2017;24(9):668–673.
 66. Reza M, Ohlsson M, Kaboteh R, et al. Bone scan index as an imaging 
biomarker in metastatic castration-resistant prostate cancer: a multicentre 
study based on patients treated with abiraterone acetate (zytiga) in clinical 
practice. Eur Urol Focus 2016;2(5):540–546.
 67. Lin C, Bradshaw T, Perk T, et al. Repeatability of quantitative 18F-NaF 
PET: a multicenter study. J Nucl Med 2016;57(12):1872–1879.
 68. Harmon SA, Perk T, Lin C, et al. Quantitative assessment of early [18F]
sodium fluoride positron emission tomography/computed romography 
response to treatment in men with metastatic prostate cancer to bone. J Clin 
Oncol 2017;35(24):2829–2837.
 69. De Giorgi U, Caroli P, Burgio SL, et al. Early outcome prediction on 18F-
fluorocholine PET/CT in metastatic castration-resistant prostate cancer 
patients treated with abiraterone. Oncotarget 2014;5(23):12448–12458.
 70. De Giorgi U, Caroli P, Scarpi E, et al. (18)F-fluorocholine PET/CT for early 
response assessment in patients with metastatic castration-resistant prostate cancer 
treated with enzalutamide. Eur J Nucl Med Mol Imaging 2015;42(8):1276–1283 
[Published correction appears in Eur J Nucl Med Mol Imaging 2015;42(8):1337–
1338.] https://doi.org/10.1007/s00259-015-3042-5.
 71. Ceci F, Herrmann K, Hadaschik B, Castellucci P, Fanti S. Therapy assessment 
in prostate cancer using choline and PSMA PET/CT. Eur J Nucl Med Mol 
Imaging 2017;44(Suppl 1):78–83.
 72. Seitz AK, Rauscher I, Haller B, et al. Preliminary results on response assess-
ment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic 
prostate cancer undergoing docetaxel chemotherapy. Eur J Nucl Med Mol 
Imaging 2018;45(4):602–612.
 73. Hope TA, Truillet C, Ehman EC, et al. 68Ga-PSMA-11 PET imaging of 
response to androgen receptor inhibition: first human experience. J Nucl 
Med 2017;58(1):81–84.
 74. Perez-Lopez R, Mateo J, Mossop H, et al. Diffusion-weighted imaging as 
a treatment response biomarker for evaluating bone metastases in prostate 
cancer: a pilot study. Radiology 2017;283(1):168–177.
 75. Blackledge MD, Tunariu N, Orton MR, et al. Inter- and intra-observer 
repeatability of quantitative whole-body, diffusion-weighted imaging (WB-
DWI) in metastatic bone disease. PLoS One 2016;11(4):e0153840.
 76. Blackledge MD, Collins DJ, Tunariu N, et al. Assessment of treatment 
response by total tumor volume and global apparent diffusion coefficient 
using diffusion-weighted MRI in patients with metastatic bone disease: a 
feasibility study. PLoS One 2014;9(4):e91779.
 77. Heller G, McCormack R, Kheoh T, et al. Circulating tumor cell 
number as a response measure of prolonged survival for metastatic 
castration-resistant prostate cancer: a comparison with prostate-specific 
antigen across five randomized phase III clinical trials. J Clin Oncol 
2018;36(6):572–580.
 78. Hofman MS, Murphy DG, Williams SG, et al. A prospective randomized 
multicentre study of the impact of gallium-68 prostate-specific membrane 
antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior 
to curative-intent surgery or radiotherapy (proPSMA study): clinical trial 
protocol. BJU Int 2018;122(5):783–793.
 79. Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C. Current status of ther-
anostics in prostate cancer. Eur J Nucl Med Mol Imaging 2018;45(3):471–495.
 80. Ferdinandus J, Eppard E, Gaertner FC, et al. Predictors of response to 
radioligand therapy of metastatic castrate-resistant prostate cancer with 
177Lu-PSMA-617. J Nucl Med 2017;58(2):312–319.
 81. Hofman MS, Violet J, Hicks RJ, et al. [177Lu]-PSMA-617 radionuclide 
treatment in patients with metastatic castration-resistant prostate cancer 
(LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol 
2018;19(6):825–833.
 82. Kim YJ, Kim YI. Therapeutic responses and survival effects of 177Lu-
PSMA-617 radioligand therapy in metastatic castrate-resistant prostate 
cancer: a meta-analysis. Clin Nucl Med 2018;43(10):728–734.
 83. Heck MM, Tauber R, Schwaiger S, et al. Treatment outcome, toxicity, and 
predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic 
castration-resistant prostate cancer. Eur Urol 2018 Nov 22 [Epub ahead of 
print].
 84. Emmett L, Crumbaker M, Ho B, et al. Results of a prospective phase 2 pilot 
trial of 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate 
cancer including imaging predictors of treatment response and patterns of 
progression. Clin Genitourin Cancer 2019;17(1):15–22.
 85. Grubmüller B, Senn D, Kramer G, et al. Response assessment using 
68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand 
therapy for metastatic castration-resistant prostate cancer. Eur J Nucl Med 
Mol Imaging 2018 Dec 19 [Epub ahead of print] https://doi.org/10.1007/
s00259-018-4236-4.
